期刊
CURRENT CANCER DRUG TARGETS
卷 6, 期 8, 页码 671-679出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800906779010227
关键词
JAK-STAT pathway; hematological malignancies; targeted therapy
类别
The development and function of hematopoictic cells depends on complex signaling pathways that are mediated by numerous cytokines and their receptors. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is prominent both in normal hematopoiesis and in hematological malignancies. SATs are phosphorylated on tyrosine residues via JAK kinases and on serine residues by a variety of scrine/threonine kinases. STATs then dimerize, translocate to the nucleus and bind DNA, initiating the transcription of target genes. STAT proteins mediate cell growth, differentiation, apoptosis, transformation, and other fundamental cell functions. Recently, mutations in the JAK2 gene driving the proliferation of the neoplastic clone have been identified in myeloproliferative disorders. In addition constitutive activation of the JAK-STAT pathway has been reported in various types of leukemias such as acute myelogenous leukemia, T-LGL leukemia, and multiple myeloma. This review describes the pathophysiological role of this pathway in hematological malignancies and the potential benefits of JAK-STA'I' inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据